INCY

Incyte Corporation

INCY, USA

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

https://www.incyte.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INCY
stock
INCY

Bellevue Group AG Has $106.94 Million Holdings in Incyte Corporation $INCY MarketBeat

Read more →
INCY
stock
INCY

AQR Capital Management LLC Purchases 1,465,286 Shares of Incyte Corporation $INCY MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$95.5714

Analyst Picks

Strong Buy

8

Buy

3

Hold

15

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

17.71

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

4.06

Low 1

High 3

Return on Equity (ROE)

-

Low

9.12 %

Low 5%

High 25%

Return on Assets (ROA)

-

Medium

6.70 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

39.87 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.36

Low 1

High 0.3

Investors

* Institutions hold a combined 93.53% of the total shares of Incyte Corporation

1.

Baker Bros Advisors LP

(15.7435%)

since

2025/06/30

2.

Vanguard Group Inc

(10.3112%)

since

2025/06/30

3.

BlackRock Inc

(9.1956%)

since

2025/06/30

4.

Dodge & Cox

(7.4741%)

since

2025/06/30

5.

State Street Corp

(5.0573%)

since

2025/06/30

6.

Dodge & Cox Stock I

(4.8308%)

since

2025/06/30

7.

AQR Capital Management LLC

(4.1999%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.6554%)

since

2025/07/31

9.

Geode Capital Management, LLC

(2.2265%)

since

2025/06/30

10.

Vanguard Small Cap Index

(2.0456%)

since

2025/07/31

11.

Vanguard 500 Index Investor

(2.0369%)

since

2025/07/31

12.

Renaissance Technologies Corp

(1.9879%)

since

2025/06/30

13.

LSV Asset Management

(1.9776%)

since

2025/06/30

14.

Amvescap Plc.

(1.7416%)

since

2025/06/30

15.

Arrowstreet Capital Limited Partnership

(1.3984%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(1.3288%)

since

2025/06/30

17.

Robeco Institutional Asset Management BV

(1.222%)

since

2025/06/30

18.

Vanguard Small Cap Growth Index Inv

(1.152%)

since

2025/07/31

19.

BB Biotech AG Ord

(1.101%)

since

2024/12/31

20.

Invesco S&P 500® Equal Weight ETF

(1.0524%)

since

2025/08/29

21.

Fidelity 500 Index

(1.0429%)

since

2025/07/31

22.

UBS Asset Mgmt Americas Inc

(1.0092%)

since

2025/06/30

23.

SPDR® S&P 500® ETF

(0.9923%)

since

2025/08/31

24.

iShares Core S&P 500 ETF

(0.987%)

since

2025/08/31

25.

SPDR® S&P Biotech ETF

(0.8726%)

since

2025/08/31

26.

Charles Schwab Investment Management Inc

(0.8558%)

since

2025/06/30

27.

Northern Trust Corp

(0.8497%)

since

2025/06/30

28.

Man Group PLC

(0.8248%)

since

2025/06/30

29.

Bellevue Group AG

(0.8042%)

since

2025/06/30

30.

Legal & General Group PLC

(0.8021%)

since

2025/06/30

31.

NORGES BANK

(0.7277%)

since

2025/06/30

32.

iShares MSCI USA Min Vol Factor ETF

(0.6946%)

since

2025/08/31

33.

Dodge & Cox Balanced I

(0.66%)

since

2025/06/30

34.

Dodge & Cox Balanced Composite

(0.66%)

since

2025/06/30

35.

iShares Biotechnology ETF

(0.5826%)

since

2025/08/31

36.

The Health Care Select Sector SPDR® ETF

(0.5618%)

since

2025/08/31

37.

VictoryShares Free Cash Flow ETF

(0.4986%)

since

2025/08/29

38.

Vanguard Institutional Index I

(0.4968%)

since

2025/07/31

39.

State St S&P 500® Indx SL Cl III

(0.4391%)

since

2025/08/31

40.

Dodge & Cox Global Stock I

(0.4286%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

2.26

EPS Estimate

1.64

EPS Difference

0.62

Surprise Percent

37.8049%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(9)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(4)
Quality
High Quality(8.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.